New Report Outlines Inspection Strategies for Devicemakers
This year should be a busy one for devicemakers as CDRH looks to enforce the UDI regulations.
“There are a number of UDI-specific quality system regulation elements that changed back in 2013,” according to John Avellanet, managing director and principal of Cerulean Associates. Avellanet said this will be the year the agency will look to ensure devicemakers are in compliance.
Even Class 1 devicemakers — which don’t need to comply with UDI requirements this year — should update forms and complaint database fields, according to an FDAnews management report.
It’s difficult to predict what other areas CDRH will look to enforce. However, Avellanet advises companies to review what areas the agency has emphasized over the last year, as well as trends over time.
Looking back over 2015, Avellanet says the most frequently cited item in 483s was CAPA, which should remain a top enforcement area. “But other areas have waxed and waned since 2012, often in response to past enforcement action,” he notes.
Avellanet expects the FDA to concentrate on four key areas during inspections this year: procedural controls and their effectiveness, supplier controls and oversight, record and data integrity and postmarket surveillance. Data integrity has been the focus of many 483s lately, he says, and devicemakers should take note.
“Last year, the FDA finished training all its CDRH investigators on the basics of data integrity,” he explains, “So I think we’re going to start seeing more and more data integrity inspections, much as we have in the pharma and biotech world for the past several years.”
He anticipates that the FDA will pay special attention to the following areas: data from automated processes associated with production or product testing; lot release data; sterility and safety data; and postmarket surveillance data.
A big trend for the agency over the coming years will be an emphasis on specialized inspections. Inspection teams will include a quality systems generalist and an expert on the device being manufactured.
Further, companies should anticipate big changes in the inspection model, as there is a “strong possibility” that the Medical Device Single Audit Program could replace the existing one.
Avellant provides his list of strategies devicemakers should keep in mind to avoid running afoul of the FDA:
Subscribe to The GMP Letter and save $200 off the regular one-year price of $1,085 — plus receive a FREE copy of our webinar: CDRH Enforcement Trends — a $287 Value!
LINKS TO KEY DOCUMENTS — You get links to documents that support GMP's articles, such as 483s, warning letters, closeout letters, guidances, FDA notices and many others.
FDANEWS DEVICE DAILY BULLETIN — This daily email alert brings you important FDA and international regulatory, legislative and business news in the medical device industry.
ONLINE ACCESS — Consider our newsletter archive your personal library! Search your current issue — and hundreds of past issues — by keyword and relevancy.
Copyright ©2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing